Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report - Takeaways - MDSpire

Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report

  • By

  • Ke Li

  • Juanjuan Hu

  • Zhiji Gan

  • Jiao Chen

  • Ye Tian

  • Ruiqing Luo

  • Xueliang Qi

  • July 15, 2026

Share

  • 1

    Efgartigimod is a neonatal Fc receptor blocker investigated for ICI-related myasthenia gravis-myositis overlap syndrome.

  • 2

    A 69-year-old female with cervical cancer developed ICI-related MG-myositis overlap syndrome after receiving tislelizumab.

  • 3

    The patient exhibited symptoms including bilateral ptosis, dysarthria, and limb weakness, with elevated serum creatine kinase.

  • 4

    After four infusions of efgartigimod, the patient's creatine kinase normalized, and her clinical scores significantly improved.

  • 5

    The treatment was well-tolerated, and the patient remained asymptomatic at the 5-month follow-up with no adverse events.

Original Source(s)

Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report

  • by Ke Li, Juanjuan Hu, Zhiji Gan, Jiao Chen, Ye Tian, Ruiqing Luo, Xueliang Qi

  • July 15, 2026

Related Content

Evaluation of orthostatic dizziness and lightheadedness in older adults: symptoms not to be taken lightly

Baroreflex sensitivity impairment in Long-COVID patients: a diagnostic tool for classifying the autonomic dysfunction spectrum

Multi-layer brain-mimicking phantom for replicating dura and pia membrane dimpling and rupture properties during neural interface implantation